INTRODUCTION
Calcitonin gene-related peptide (CGRP) is most likely involved in migraine. The US Food and Drug Administration and the European Medicines Agency have approved injections of several antibodies to the CGRP receptor or ligand for the prophylactic treatment of migraine. 2 The oral small molecule CGRP receptor antagonist telcagepant was shown to be effective for the acute treatment of migraine attacks in randomized, controlled trials. 3, 4 However, its development was halted when several participants developed liver toxicity in a Phase IIb trial of the drug for migraine prophylaxis. 5, 6 This article focuses on 2 other small molecule CGRP receptor antagonists, ubrogepant and rimegepant, which remain in late phase testing for the acute treatment of migraine. In the first half of 2018, the main results of large Phase 3 trials of these drugs were presented as abstracts at several medical conferences. We review the small effect sizes in these studies, discuss the difference between statistical and clinical significance, and reflect on the lack of candid discussion about the low efficacy of these drugs. 100 mg of ubrogepant and placebo, and enrolled 1327 and 1355 participants, respectively. 7, 8 The BHV3000-301 and BHV3000-302 trials of rimegepant (Biohaven) studied 75 mg of rimegepant and placebo, and enrolled 1084 and 1072 participants, respectively. 9 Media reports described trial results for these new gepants in positive terms, with headlines such as "Ubrogepant Safe, Effective for Migraine in Second Phase 3 Trial" 10 and "Positive Phase 3 Results for Rimegepant in Acute Migraine." 11 Opinion leaders and study investigators who were quoted in these and other news stories expressed enthusiasm about the results, referring to differences between the active drug and placebo that were "highly statistically significant." 11 One expert suggested "… ubrogepant may provide a new option for those having tolerability issues with current migraine-specific treatments" 10 and
another commented that it "absolutely has a place in the acute treatment of migraine." 10 For both drugs, the raw efficacy data were presented as the number and percentage of patients in each treatment group who were pain-free at 2 hours after treatment (see Table 1 ). Emphasis was placed on the statistical significance of the results, even though P values are not an appropriate way to judge the clinical significance of trial results. To give just 1 example: "compared with placebo, pain freedom at 2 hours in rimegepant group reached a significance of P = .0006. Freedom from most bothersome symptom was significant at P < .0001." 12 Although statistically significant, it is doubtful that the small differences between these drugs and placebo are clinically meaningful. In addition to depending on the difference in outcomes between treatment groups, P values also depend on the number of participants in a trial. In large trials small, clinically irrelevant differences can easily achieve statistical significance. 13 This seems to be the case with the ubrogepant and rimegepant studies, which were very large in order to evaluate tolerability. To help patients and doctors judge the clinical relevance of trial results, researchers should provide a summary of the mean data for each treatment group, along with a measure of the difference between drug and placebo. Therapeutic gain (TG) serves this purpose well. There is nothing tricky about TG: it is simply the difference between percentage effect of active drug minus percentage effect of placebo. For the Biohaven 3000-301 trial of rimegepant, for example, 19% of participants were pain-free 2 hours after treatment with 75 mg of rimegapant, compared with 14% of those who received placebo. Thus, the TG was 5%.
Ideally, the TG should be presented with 95% confidence intervals so that readers can see the full range of possibilities that are compatible with the data. For example, with rimegepant the 95% CI is 0.5%-9%. Often another measure of net benefit is presented, the so-called "number needed to treat" (NNT). The NNT is simply the reciprocal of the TG. In the example above, the NNT is 1/0.05, or 20. This means that 20 people would need to be treated with 75 mg of rimegepant in order for 1 of them to have a pain-free outcome at 2 hours that is attributable to the drug (as opposed to placebo or natural history). Table 1 illustrates the proportion of participants in randomized clinical trials of selected treatments for acute migraine who are pain-free 2 hours following treatment with active drug or placebo and calculates the TG with 95% confidence intervals for each drug. Pain-free at 2 hours has been used as the primary efficacy outcome measure in most randomized controlled trials of newer treatments for migraine (ubrogepant, rimegepant) and in older trials of other drugs used to treat acute migraine (acetaminophen, aspirin, diclofenac, sumatriptan, eletriptan, and rizatriptan).
COMPARING THE GEPANTS TO OTHER TREATMENTS
It can be difficult to compare drugs and detect minor differences in a meta-analysis. As seen in Table 1 , although there is overlap for the 95% confidence intervals for the therapeutic gain of the 2 gepants with those of several nonspecific antimigraine drugs (acetaminophen, aspirin, and diclofenac), it is highly unlikely that either gepant is more effective than these alternative nonspecific antimigraine drugs. Furthermore, the 2 gepants are considerably less effective than sumatriptan 50 or 100 mg, eletriptan 40 mg, or rizatriptan 10 mg.
Why are the effect sizes for ubrogepant and rimegepant so much smaller than those of telcagepant, the first oral CGRP receptor antagonist? Pooled results from 4 trials of telcagepant, with doses ranging from 280 to 300 mg, show a therapeutic gain of 17% (95% CI 14%-19%). 19 This is much higher than the 5%-9% therapeutic gains seen for ubrogepant and rimegepant. The treatment principle, antagonism of the CGRP receptor, is the same, so effect sizes should be comparable, yet they are not. Two possible explanations could be: (1) the tested doses of ubrogepant and rimegepant are too low, but increasing the dose of rimegepant from 75 mg to up to 600 mg did not increase efficacy in one phase 2 trial; 21 (2) slow oral absorption, but it is an unlikely cause because the median T max for ubrogepant is 0.7-1.5 hours. 22 Additional work is needed to investigate the cause(s) for low efficacy, including in vivo investigations in humans of the ability of these drugs to antagonize capsaicin-induced increases in dermal blood flow.
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CONCLUSION
Are the effects of ubrogepant and rimegepant clinically relevant? They appear to have far lower efficacy than the triptans, and are not more effective than simple analgesics that can be purchased without a prescription. Their purported safety or tolerability advantages over triptans are speculative and likely to be relevant for only a small proportion of migraineurs. We therefore find it justified to suggest that it is very difficult to see the Emperor's new gepants.
